Literature DB >> 17320156

Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma.

Hyun S Shvartsman1, Charlotte C Sun, Diane C Bodurka, Vrinda Mahajan, Marta Crispens, Karen H Lu, Michael T Deavers, Anais Malpica, Elvio G Silva, David M Gershenson.   

Abstract

BACKGROUND: Serous ovarian tumors of low malignant potential (STLMP) frequently coexist with low-grade serous carcinoma of the ovary (LGSC) and, when they recur, frequently do so as LGSC. The purpose of this study was to compare the outcomes of patients with these two tumor types.
METHODS: All patients with stages II-IV LGSC (group 1) or with STLMP that recurred as LGSC (group 2) seen at our institution from 1973 to 2003 were identified, and demographic data were obtained. For group 1, progression-free and overall survival times were calculated from the date of primary diagnosis to the date of disease progression/recurrence or the date of last contact/death, respectively. For group 2, progression-free and overall survival times were calculated from the date of first relapse as a LGSC to the date of progression or the date of last contact/death, respectively. The method of Kaplan and Meier was used to estimate survival, and the log-rank test was used to compare differences between survival curves.
RESULTS: We identified 112 patients in group 1 and 41 in group 2. There were no statistically significant differences between the two groups in median age (42.7 vs. 45.4 years [at relapse]; P=0.37), progression-free survival time (19.5 vs. 25 months; P=0.92), or overall survival time (81.8 vs. 82.8 months; P=0.84).
CONCLUSIONS: The age at diagnosis, progression-free survival time, and overall survival time associated with newly diagnosed stages II-IV LGSC of the ovary are similar to those of STLMP that recur as LGSC, providing further evidence of an association between these two tumor types.

Entities:  

Mesh:

Year:  2007        PMID: 17320156     DOI: 10.1016/j.ygyno.2007.01.030

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  23 in total

1.  Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum.

Authors:  David M Gershenson; Charlotte C Sun; Revathy B Iyer; Anais L Malpica; John J Kavanagh; Diane C Bodurka; Kathleen Schmeler; Michael Deavers
Journal:  Gynecol Oncol       Date:  2012-03-06       Impact factor: 5.482

Review 2.  Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems.

Authors:  Russell Vang; Ie-Ming Shih; Robert J Kurman
Journal:  Adv Anat Pathol       Date:  2009-09       Impact factor: 3.875

3.  The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.

Authors:  Erin R King; Zhifei Zu; Yvonne T M Tsang; Michael T Deavers; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Gynecol Oncol       Date:  2011-07-02       Impact factor: 5.482

4.  Low-grade serous carcinomas of the ovary contain very few point mutations.

Authors:  Siân Jones; Tian-Li Wang; Robert J Kurman; Kentaro Nakayama; Victor E Velculescu; Bert Vogelstein; Kenneth W Kinzler; Nickolas Papadopoulos; Ie-Ming Shih
Journal:  J Pathol       Date:  2011-12-20       Impact factor: 7.996

5.  Long-term Behavior of Serous Borderline Tumors Subdivided Into Atypical Proliferative Tumors and Noninvasive Low-grade Carcinomas: A Population-based Clinicopathologic Study of 942 Cases.

Authors:  Russell Vang; Charlotte G Hannibal; Jette Junge; Kirsten Frederiksen; Susanne K Kjaer; Robert J Kurman
Journal:  Am J Surg Pathol       Date:  2017-06       Impact factor: 6.394

Review 6.  The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Pathol       Date:  2016-04       Impact factor: 4.307

7.  BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.

Authors:  Rachel N Grisham; Gopa Iyer; Karuna Garg; Deborah Delair; David M Hyman; Qin Zhou; Alexia Iasonos; Michael F Berger; Fanny Dao; David R Spriggs; Douglas A Levine; Carol Aghajanian; David B Solit
Journal:  Cancer       Date:  2012-08-28       Impact factor: 6.860

8.  The anterior gradient homolog 3 (AGR3) gene is associated with differentiation and survival in ovarian cancer.

Authors:  Erin R King; Celestine S Tung; Yvonne T M Tsang; Zhifei Zu; Gabriel T M Lok; Michael T Deavers; Anais Malpica; Judith K Wolf; Karen H Lu; Michael J Birrer; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  Am J Surg Pathol       Date:  2011-06       Impact factor: 6.394

9.  The role of secondary cytoreduction in low-grade serous ovarian cancer or peritoneal cancer.

Authors:  Erin K Crane; Charlotte C Sun; Pedro T Ramirez; Kathleen M Schmeler; Anais Malpica; David M Gershenson
Journal:  Gynecol Oncol       Date:  2014-11-08       Impact factor: 5.482

10.  KRAS (but not BRAF) mutations in ovarian serous borderline tumour are associated with recurrent low-grade serous carcinoma.

Authors:  Yvonne T Tsang; Michael T Deavers; Charlotte C Sun; Suet-Yan Kwan; Eric Kuo; Anais Malpica; Samuel C Mok; David M Gershenson; Kwong-Kwok Wong
Journal:  J Pathol       Date:  2013-12       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.